The study showed lower reoperation rates for the Mobi-C and better mean neck disability improvement through four years.
Hyun Bae, MD, medical director and director of spine education at Cedars-Sinai in Los Angeles, presented the data earlier this month at the North American Spine Society annual meeting.
The Mobi-C is the first cervical disc replacement device approved by the FDA for both one- and two-level indications.
More Articles on Devices:
K2M, Amedica Reach European Distribution Agreement for Biomaterial Spinal Fusion Devices
Zimmer Holdings Reports Decreased Earnings, Spine Sales in Q3
15 New Spine, Orthopedic Device Launches & Releases
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
